| 2026-09-01in 7 d | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years | ARDXArdelyx | Phase 3 | Irritable Bowel Syndrome With Constipation (IBS-C) | Active, not recruiting |
| 2026-09-01in 7 d | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | INCYIncyte Corporation | Phase 3 | Diffuse Large B-Cell Lymphoma | Active, not recruiting |
| 2026-09-01in 7 d | A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | NVONovo Nordisk A/S | Phase 2 | Chronic Kidney Disease | Recruiting |
| 2026-09-01in 7 d | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | PFEPfizer | Phase 1/2 | Breast Cancer | Active, not recruiting |
| 2026-09-03in 9 d | Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. | AMGNAmgen | Phase 1 | Healthy Participants | Active, not recruiting |
| 2026-09-03in 9 d | A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer | AZNAstraZeneca | Phase 1 | Glioblastoma | Active, not recruiting |
| 2026-09-03in 9 d | A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants | INCYIncyte Corporation | Phase 1 | Healthy Participants | Recruiting |
| 2026-09-03in 9 d | A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight | NVONovo Nordisk A/S | Phase 1 | Overweight | Active, not recruiting |
| 2026-09-03in 9 d | A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults | PFEPfizer | Phase 1 | Healthy Adults, Healthy | Recruiting |
| 2026-09-03in 9 d | Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | SNYSanofi | Phase 2 | Systemic Lupus Erythematosus | Active, not recruiting |
| 2026-09-05in 11 d | A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | BMYBristol-Myers Squibb | Phase 1/2 | Solid Tumors | Recruiting |
| 2026-09-05in 11 d | A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | HLUN-B.COH. Lundbeck A/S | Phase 3 | Chronic Migraine in Children | Recruiting |
| 2026-09-05in 11 d | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) | IBAB.BRIon Beam Applications | Not applicable | Solid Tumors | Active, not recruiting |
| 2026-09-05in 11 d | Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection | MDAIAI-Spectral | — | Age-Related (Dry) Macular Degeneration | Recruiting |
| 2026-09-06in 12 d | A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65 | ALK-B.COALK-Abelló A/S | Phase 3 | Allergic Rhinoconjunctivitis, Allergic Rhinitis | Active, not recruiting |
| 2026-09-07in 13 d | A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults | AZNAstraZeneca | Phase 1 | Healthy Participants | Active, not recruiting |
| 2026-09-10in 16 d | A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults | PFEPfizer | Phase 1 | Healthy Adults | Not yet recruiting |
| 2026-09-10in 16 d | Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan | SNYSanofi | — | Fabry Disease | Active, not recruiting |
| 2026-09-12in 18 d | A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes | NVONovo Nordisk A/S | Phase 1 | Type 1 Diabetes | Active, not recruiting |
| 2026-09-12in 18 d | A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding Women | PFEPfizer | Phase 1 | Healthy Participant | Recruiting |
| 2026-09-15in 21 d | Bioequivalence Study Between YHP2508C and YHR2603 in Healthy Subjects | 000100.KSYuhan Corporation | Phase 1 | Healthy Subjects | Not yet recruiting |
| 2026-09-15in 21 d | A Trial of Lu AG13909 in Adult Participants With Cushing's Disease | HLUN-B.COH. Lundbeck A/S | Phase 2 | Cushing's Disease | Recruiting |
| 2026-09-15in 21 d | A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes | PFEPfizer | Phase 1/2 | Obesity | Recruiting |
| 2026-09-17in 23 d | A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234 | AZNAstraZeneca | Phase 1 | Healthy Participants | Active, not recruiting |
| 2026-09-17in 23 d | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Type 1 Diabetes | Recruiting |
| 2026-09-18in 24 d | iGlarLixi CGM Study in Chinese T2D Individuals After OADs | SNYSanofi | Phase 4 | Type 2 Diabetes | Recruiting |
| 2026-09-21in 27 d | CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) | CRDLCardiol Therapeutics Inc. | Phase 3 | Recurrent Pericarditis | Recruiting |
| 2026-09-21in 27 d | Appetite and Cognition Response to a Breakfast Cereal | GISGeneral Mills | Not applicable | Cognition | Recruiting |
| 2026-09-21in 27 d | A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India. | PFEPfizer | — | Dwarfism, Pituitary | Recruiting |
| 2026-09-22in 28 d | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | MRNAModernaTX, Inc. | Phase 1/2 | Norovirus Acute Gastroenteritis | Active, not recruiting |
| 2026-09-22in 28 d | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia | ONCBeOne Medicines | Phase 2 | Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory | Active, not recruiting |
| 2026-09-22in 28 d | Korean Post-marketing Surveillance for Xeljanz XR | PFEPfizer | — | Psoriatic Arthritis | Recruiting |
| 2026-09-22in 28 d | Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study | SNYSanofi | — | Prurigo Nodularis | Active, not recruiting |
| 2026-09-23in 29 d | A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants. | AZNAstraZeneca | Phase 1 | Healthy | Recruiting |
| 2026-09-23in 29 d | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | PFEPfizer | Phase 2 | Prostate Cancer | Active, not recruiting |
| 2026-09-23in 29 d | Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone | PFEPfizer | — | Pediatric Growth Hormone Deficiency | Active, not recruiting |
| 2026-09-25in 31 d | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 | VIRVir Biotechnology, Inc. | Phase 1 | Hepatic Impairment, Cirrhosis | Recruiting |
| 2026-09-27in 33 d | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | BIIBBiogen | Phase 3 | Systemic Lupus Erythematosus | Active, not recruiting |
| 2026-09-27in 33 d | A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults | ONCBeOne Medicines | Phase 1 | Healthy Volunteers | Recruiting |
| 2026-09-28in 34 d | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2 | AZNAstraZeneca | Phase 2 | Gastric Cancer | Active, not recruiting |
| 2026-09-28in 34 d | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | INCYIncyte Corporation | Phase 2 | Cutaneous Squamous Cell Carcinoma | Active, not recruiting |
| 2026-09-28in 34 d | An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) | MLTXMoonLake Immunotherapeutics AG | Phase 3 | Hidradenitis Suppurativa | Active, not recruiting |
| 2026-09-28in 34 d | A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease | OCGNOcugen | Phase 2/3 | Stargardt Disease | Active, not recruiting |
| 2026-09-28in 34 d | Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants | SNYSanofi | Phase 1 | Graft-Versus-Host Disease | Not yet recruiting |
| 2026-09-29in 35 d | Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study | SNYSanofi | Phase 2 | Asthma | Active, not recruiting |
| 2026-09-30in 36 d | A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | 4568.TDaiichi Sankyo | Phase 1/2 | Extensive Stage-small Cell Lung Cancer | Recruiting |
| Sep 2026≤ 36 d | A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors | ABBVAbbVie | Phase 1 | Solid Tumors | Active, not recruiting |
| Sep 2026≤ 36 d | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab | ABBVAbbVie | Phase 3 | Psoriatic Arthritis | Recruiting |
| Sep 2026≤ 36 d | A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants | ABBVAbbVie | Phase 1 | Healthy Volunteer | Active, not recruiting |
| Sep 2026≤ 36 d | A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting | ABBVAbbVie | — | Crohn's Disease | Recruiting |
| Sep 2026≤ 36 d | A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants | ABBVAbbVie | Phase 1 | Healthy Volunteer | Recruiting |
| Sep 2026≤ 36 d | A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants | ABBVAbbVie | Phase 1 | Healthy Volunteer | Recruiting |
| Sep 2026≤ 36 d | Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation | ABVXAbivax S.A. | Phase 1 | Healthy | Recruiting |
| Sep 2026≤ 36 d | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder | ALKSAlkermes, Inc. | Phase 3 | Schizophrenia | Recruiting |
| Sep 2026≤ 36 d | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma | APGEApogee Therapeutics, Inc. | Phase 1 | Asthma | Active, not recruiting |
| 2026-09-30in 36 d | Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia | ARWRArrowhead Pharmaceuticals | Phase 1/2 | Hyperlipidemia; Mixed | Recruiting |
| Sep 2026≤ 36 d | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV | AVIRAtea Pharmaceuticals, Inc. | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION | Active, not recruiting |
| 2026-09-30in 36 d | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | AZNAstraZeneca | Phase 3 | Lung Cancer | Active, not recruiting |
| 2026-09-30in 36 d | Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC | AZNAstraZeneca | Phase 3 | Hepatocellular Carcinoma | Active, not recruiting |
| 2026-09-30in 36 d | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | AZNAstraZeneca | Phase 3 | Lung Cancer | Recruiting |
| 2026-09-30in 36 d | Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study | AZNAstraZeneca | — | Asthma | Recruiting |
| 2026-09-30in 36 d | Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia | AZNAstraZeneca | — | Asthma | Active, not recruiting |
| 2026-09-30in 36 d | An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients | AZNAstraZeneca | — | Asthma | Active, not recruiting |
| 2026-09-30in 36 d | A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia | AZNAstraZeneca | Phase 2 | Dyslipidaemia | Active, not recruiting |
| 2026-09-30in 36 d | Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy) | AZNAstraZeneca | — | Neurofibromatosis Type 1 | Recruiting |
| 2026-09-30in 36 d | Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | AZNAstraZeneca | — | Respiratory (Chronic Obstructive Pulmonary Disease) | Recruiting |
| 2026-09-30in 36 d | Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil | AZNAstraZeneca | — | Hyperkalemia | Recruiting |
| 2026-09-30in 36 d | HER2-positive Metastatic Breast Cancer in Kazakhstan | AZNAstraZeneca | — | Breast Cancer | Not yet recruiting |
| 2026-09-30in 36 d | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | BIIBBiogen | Phase 3 | Systemic Lupus Erythematosus | Active, not recruiting |
| 2026-09-30in 36 d | Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study | BJDXBluejay Diagnostics, Inc. | — | Sepsis, Septic Shock | Active, not recruiting |
| 2026-09-30in 36 d | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | BMYBristol-Myers Squibb | Phase 1/2 | Solid Tumors | Active, not recruiting |
| 2026-09-30in 36 d | Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada | BMYBristol-Myers Squibb | — | Lung Cancer | Active, not recruiting |
| 2026-09-30in 36 d | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | CCCCC4 Therapeutics, Inc. | Phase 1 | Multiple Myeloma | Active, not recruiting |
| Sep 2026≤ 36 d | HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC) | CDNACareDx | Not applicable | Heart Transplant, Immunosuppression, Allograft | Not yet recruiting |
| Sep 2026≤ 36 d | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | CGEMCullinan Therapeutics Inc. | Phase 1 | Multiple Myeloma | Active, not recruiting |
| 2026-09-30in 36 d | Study of CHS-114 in Participants With Advanced Solid Tumors | CHRSCoherus Oncology, Inc. | Phase 1 | Solid Tumors | Active, not recruiting |
| Sep 2026≤ 36 d | 6-month Clinical Investigation Assessing the Efficacy of an Antimicrobial Mouthrinse in Reducing Established Plaque and Improving Gum Health | CLColgate Palmolive | Phase 4 | Gingivitis | Recruiting |
| Sep 2026≤ 36 d | A Study to Investigate Stannous Fluoride Containing Toothpaste on Antibacterial Effects in the Different Regions of the Mouth | CLColgate Palmolive | Phase 3 | Gingivitis | Not yet recruiting |
| 2026-09-30in 36 d | Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in a Population With High Plaque/Low Gingivitis and High Plaque/High Gingivitis | CLColgate Palmolive | Phase 4 | Gingivitis | Recruiting |
| Sep 2026≤ 36 d | Comparative Efficacy of Different Dentin Occluding Toothpaste Technologies | CLColgate Palmolive | Phase 3 | Dentinal Sensitivity, Dentinal Hypersensitivity | Recruiting |
| Sep 2026≤ 36 d | A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) | CORTCorcept Therapeutics | Phase 2 | MASH / Nonalcoholic Steatohepatitis | Active, not recruiting |
| Sep 2026≤ 36 d | Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies | CORTCorcept Therapeutics | Phase 1/2 | Neoplasms | Recruiting |
| Sep 2026≤ 36 d | AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | CYTKCytokinetics | Phase 2 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | Recruiting |
| Sep 2026≤ 36 d | DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy | DSGNDesign Therapeutics, Inc. | Phase 2 | Fuchs Endothelial Corneal Dystrophy, Fuchs | Recruiting |
| Sep 2026≤ 36 d | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | EWTXEdgewise Therapeutics, Inc. | Phase 2 | Becker Muscular Dystrophy | Active, not recruiting |
| Sep 2026≤ 36 d | Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | GILDGilead Sciences | Phase 2 | Chronic Hepatitis B | Active, not recruiting |
| Sep 2026≤ 36 d | Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) | GILDGilead Sciences | Phase 2 | Lung Cancer | Active, not recruiting |
| Sep 2026≤ 36 d | Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis | GKOSGlaukos Corporation | Phase 2 | Demodex Blepharitis | Recruiting |
| Sep 2026≤ 36 d | Aleniglipron Phase 2 in Type 2 Diabetes Mellitus | GPCRGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Phase 2 | Obesity | Active, not recruiting |
| Sep 2026≤ 36 d | A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years | HLNHALEON | Phase 1 | Pain | Recruiting |
| 2026-09-30in 36 d | A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia | HLUN-B.COH. Lundbeck A/S | Phase 1/2 | Congenital Adrenal Hyperplasia | Recruiting |
| 2026-09-30in 36 d | The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI | HTFLHeartFlow, Inc. | — | Coronary Artery Disease | Recruiting |
| 2026-09-30in 36 d | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | IBRXImmunityBio, Inc. | Phase 1/2 | Bladder Cancer | Active, not recruiting |
| Sep 2026≤ 36 d | Study of Bitopertin in Participants With EPP or XLP (APOLLO) | IRONDisc Medicine, Inc | Phase 3 | Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | Active, not recruiting |
| 2026-09-30in 36 d | CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical Prostatectomy | ISRGIntuitive Surgical | — | Prostate Cancer | Active, not recruiting |
| Sep 2026≤ 36 d | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | KPTIKaryopharm Therapeutics Inc | Phase 2 | Myelofibrosis | Active, not recruiting |
| Sep 2026≤ 36 d | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | LLYEli Lilly and Company | Phase 2 | Overweight | Active, not recruiting |
| Sep 2026≤ 36 d | A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) | LLYEli Lilly and Company | Phase 1 | Type 1 Diabetes | Recruiting |
| Sep 2026≤ 36 d | A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) | LLYEli Lilly and Company | Phase 3 | Perennial Allergic Rhinitis (PAR) | Active, not recruiting |
| Sep 2026≤ 36 d | A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's Disease | LLYEli Lilly and Company | — | Alzheimer's Disease | Not yet recruiting |
| Sep 2026≤ 36 d | A Study of Food Effect on Tersolisib (LY4064809) in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy | Active, not recruiting |
| Sep 2026≤ 36 d | A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease | MAZEMaze Therapeutics | Phase 2 | Proteinuric Kidney Disease | Recruiting |
| 2026-09-30in 36 d | A Retrospective Study to Characterize Participants With Propionic Acidemia | MRNAModernaTX, Inc. | — | Propionic Acidemia | Recruiting |
| 2026-09-30in 36 d | Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study. | NVONovo Nordisk A/S | — | Obesity | Enrolling by invitation |
| 2026-09-30in 36 d | Korean Real-world Study on MASLD/MASH Outcomes. | NVONovo Nordisk A/S | — | MASLD/MASH | Active, not recruiting |
| Sep 2026≤ 36 d | Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA. | NYXH.BRNyxoah S.A. | Not applicable | Obstructive Sleep Apnea | Active, not recruiting |
| 2026-09-30in 36 d | A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants | ONCBeOne Medicines | Phase 1 | Healthy Volunteers | Recruiting |
| Sep 2026≤ 36 d | Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | ORICORIC Pharmaceuticals | Phase 1/2 | Solid Tumors | Recruiting |
| Sep 2026≤ 36 d | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | PCSAProcessa Pharmaceuticals | Phase 2 | Breast Cancer | Recruiting |
| 2026-09-30in 36 d | Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis | PFEPfizer | — | Psoriatic Arthritis, Juvenile, Polyarticular Juvenile Idiopathic Arthritis | Recruiting |
| 2026-09-30in 36 d | A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany | PFEPfizer | — | ATTR Amyloidosis | Active, not recruiting |
| 2026-09-30in 36 d | Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos | PFEPfizer | — | Respiratory Syncytial Virus | Active, not recruiting |
| Sep 2026≤ 36 d | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) | RGNXREGENXBIO Inc. | Phase 2/3 | Duchenne Muscular Dystrophy | Active, not recruiting |
| Sep 2026≤ 36 d | Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study | RXSTRxSight, Inc. | — | Aphakia Cataract | Enrolling by invitation |
| 2026-09-30in 36 d | A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX) | SGHTSight Sciences, Inc. | Not applicable | Glaucoma | Active, not recruiting |
| Sep 2026≤ 36 d | Study to Assess SLN124 in Patients With Polycythemia Vera | SLNSilence Therapeutics plc | Phase 1/2 | Polycythemia Vera | Active, not recruiting |
| Sep 2026≤ 36 d | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | SNDXSyndax Pharmaceuticals | Phase 2 | Idiopathic Pulmonary Fibrosis | Active, not recruiting |
| 2026-09-30in 36 d | Post-Market Clinical Study to Evaluate the Safety and Effectiveness of REFLEX ULTRA 45 for Coblation Inferior Turbinate Reduction in China | SNNSmith & Nephew, Inc. | Not applicable | Nasal Obstruction Due to Inferior Turbinate Hypertrophy | Recruiting |
| 2026-09-30in 36 d | Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain | SNYSanofi | — | Atopic Dermatitis | Active, not recruiting |
| 2026-09-30in 36 d | Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants | SNYSanofi | Phase 1 | Healthy Volunteers | Active, not recruiting |
| Sep 2026≤ 36 d | Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | SUPNSupernus Pharmaceuticals, Inc. | Phase 3 | Attention-Deficit/Hyperactivity Disorder | Active, not recruiting |
| Sep 2026≤ 36 d | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | TNGXTango Therapeutics, Inc. | Phase 1/2 | Lung Cancer | Active, not recruiting |
| Sep 2026≤ 36 d | Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers | TRAWTraws Pharma, Inc. | Phase 1 | Healthy Volunteer | Recruiting |
| Sep 2026≤ 36 d | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations | TYRATyra Biosciences, Inc | Phase 1 | Cholangiocarcinoma | Active, not recruiting |
| Sep 2026≤ 36 d | Monthly Dosing of Atacicept in IgAN | VERAVera Therapeutics, Inc. | Phase 2 | IgA Nephropathy (IgAN), Berger Disease | Active, not recruiting |
| Sep 2026≤ 36 d | Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) | VNDAVanda Pharmaceuticals | Phase 3 | Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders | Active, not recruiting |
| Sep 2026≤ 36 d | Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis | VNDAVanda Pharmaceuticals | Phase 2 | Onychomycosis of Toenail | Active, not recruiting |
| Sep 2026≤ 36 d | An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye | VNDAVanda Pharmaceuticals | Phase 2 | Dry Eye | Recruiting |
